Chinese HIV-Drug Developer Jiangsu Aidea Eyes Hong Kong IPO as Springboard to US and Europe
Jiangsu Aidea, a Chinese developer of anti-HIV and AIDS treatments listed on Shanghai’s Star Market, plans a Hong Kong IPO to help fund expansion into US and European markets.